Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials
Authors' conclusion
Pooled results from three studies of adults with T2D demonstrated that iGlarLixi provided similar clinically meaningful improvements in glycaemic control without increased hypoglycaemia risk, regardless of concomitant use of SGLT2is.
Study context
- Population
- People with T2D initiating iGlarLixi in LixiLan-G (advancing from a GLP-1 RA), SoliMix and LixiLan ONE CAN (advancing from basal insulin)3 trials
- Participants
- 219 vs 746
- Comparison
- iGlarLixi with vs without concomitant SGLT2i
- SGLT2i usersn = 219
- SGLT2i non-usersn = 746reference
- Outcome
- LS mean change in HbA1c from baseline
- Follow-up
- Week 26
Pooled result
As reported in the abstract
Users
−1.2
least squares mean change · 95% CI −1.4 %, −1.1 % · %
Non-users
−1.2
least squares mean change · 95% CI −1.2 %, −1.1 % · %
Further pooled results
- Changes in body weight, fasting glucose and post-prandial glucose similar between groups
Safety
- Hypoglycaemic events similar between groups
Original publication
Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials. Diabetes Res Clin Pract. Published 5 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →